biospatial’s vice president of growth Andrew Schafer sat down with the CEO of [InterveXion Therapeutics](http://intervexion.com/) and [Applied Clinical Trials](https://www.appliedclinicaltrialsonline.com/) to discuss how [biospatial’s platform](https://www.biospatial.io/clinical-trials/) was used to bolster site selection efforts for a Phase 2 methamphetamine overdose study.

The [discussion](https://www.appliedclinicaltrialsonline.com/view/utilization-of-ems-data-in-site-selection) covers how biospatial, [Syneos Health](https://www.syneoshealth.com/), and InterveXion Therapeutics formed a partnership for this study, how EMS data accessible through the biospatial platform can be used to refine site selection efforts, and how electronic Patient Care Report (ePCR) data was used for patient recruitment.

To learn more about biospatial’s partnership with Syneos Health and InterveXion Therapeutics, read our press release on the subject [here](https://www.biospatial.io/biospatial-announces-case-study-with-intervexion-therapeutics-and-syneos-health/).

Find out more about the Phase II Meth-OD study [here](http://intervexion.com/2021/09/intervexion-enrolls-first-patient-meth-od-phase-2-study-ixt-m200-methamphetamine-overdose/).